Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $71.00
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 9, 26 |
Daily · Wilder smoothing
| Evercore ISI Group |
| maintain |
| Outperform |
| Outperform |
| Aug 10, 26 | Evercore ISI Group | maintain | Outperform | Outperform |
| Jul 10, 26 | Evercore ISI Group | maintain | Outperform | Outperform |
| Apr 10, 26 | Evercore ISI Group | maintain | Outperform | Outperform |
| Oct 20, 25 | Evercore ISI Group | maintain | Outperform | Outperform |
| Oct 9, 25 | Evercore ISI Group | maintain | Outperform | Outperform |
| Oct 2, 25 | B of A Securities | maintain | Underperform | Underperform |
| Sep 5, 25 | Evercore ISI Group | maintain | Outperform | Outperform |
| Jul 21, 25 | B of A Securities | maintain | Underperform | Underperform |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 46.84 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 66.75 | Oscillator | Neutral |
| Williams %R (14) | -33.33 | Oscillator | Neutral |
| MACD (12, 26, 9) | -1.30 (Hist 0.46) | Oscillator | Buy |
| Average Directional Index (14) | 32.59 (+DI 14.7 / -DI 21.2) | Trend | Strong Sell |
| EMA 20 | 71.26 | MA | Sell |
| SMA 20 | 70.93 | MA | Buy |
| EMA 50 | 73.88 | MA | Strong Sell |
| SMA 50 | 75.35 | MA | Strong Sell |
| SMA 200 | 71.93 | MA | Sell |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | CNS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 21.6x | 24.0x · sector 20.4x | In line |
| Forward P/E (FY26E) | 21.1x | EPS est. 3.37 | In line |
| Price / Book | 6.2x | 10.3x | Discount |
| Price / Sales | 6.0x | 7.1x | Discount |
| EV / EBITDA | 15.8x | 17.8x | In line |
| Return on equity | 29.8% | — | Top tier |
| Gross margin | 84.7% | 51.0% | Above hist. |
| Debt / Equity | 0.23 | 0.28 | Conservative |
| Piotroski / Altman Z | 4/9 | Z 12.19 | Safe zone |
Discounted cash flow model
| 4 | Oct 2, 2026 | 2026-10-02 16:12:24 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:12:16 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:12:05 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:11:58 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:11:50 | View |
| 4 | Oct 2, 2026 | 2026-10-02 16:11:38 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology and Phase 2 Clinical Pipelines at BIO-Europe 2026PR NewswireSEOUL, South Ko
Cohen & Steers generated $1.6 billion in third-quarter net inflows. The institutional pipeline reached $1.9 billion.
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations or other uncommon EGFR mutations and active central nervous system (CNS) metastases. The data will be.
Schwab US Dividend Equity ETF has outperformed SPY YTD, up over 25% versus SPY's ~12%. SCHD's top holdings, including DINO, APA, and TXN, have delivered strong double- and triple-digit returns, driving ETF performance. Dividend growth remains robust, with eight SCHD constituents announcing increases averaging 5.73%, supporting the ETF's income appeal.
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR NewswireINDIANAPOLIS, Oct. 18, 2026F
Cohen & Steers trades at 19x PE, well above the 10x multiples you can find in the industry, corroborated by the Seeking Alpha 10.18x forward non-GAAP PE peer average. CNS's core asset classes—preferreds and real estate—are highly rate-sensitive, with recent cycles demonstrating significant downside risk, and this one being analogous. Falling fee rates and pressured AUMs, despite net inflows, limit operating leverage and earnings upside for CNS on a go-forward basis.
Cohen & Steers, Inc. ( CNS ) Q3 2026 Earnings Call October 16, 2026 10:00 AM EDT Company Participants Brian Meta Amit Muni - Chief Financial Officer John Cheigh - President & Chief Investment Officer Joseph Harvey - CEO & Director Conference Call Participants John Dunn - Evercore ISI Institutional Equities, Research Division Ivory Gao - BofA Securities, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers Third Quarter 2026 Earnings Call.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 15, 2026 | 0.89 | 0.89 | Beat 0.0% | $156.4M |
| Jul 16, 2026 | 0.86 | 0.85 | Miss -0.6% | $151.8M |
| Apr 16, 2026 | 0.81 | 0.79 | Miss -2.5% | $144.3M |
| Jan 22, 2026 | 0.81 | 0.81 | Beat 0.0% | $143.8M |
| Oct 16, 2025 | 0.78 | 0.81 | Beat 4.5% | $141.7M |
| Jul 17, 2025 | 0.75 | 0.73 | Miss -2.7% | $142.4M |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 2, 26 | Villani Edmond D | director | G-Gift | 442 | — |
| Oct 1, 26 | Villani Edmond D | director | A-Award | 375 | — |
| Oct 2, 26 | Villani Edmond D | director | G-Gift | 442 | — |
| Oct 1, 26 | Dolly Lisa | director | A-Award | 375 | — |
| Oct 1, 26 | Thissen Karen Wilson | director | A-Award | 375 | — |
| Oct 1, 26 | Smith Dasha | director | A-Award | 375 | — |
| Oct 1, 26 | Aggarwal Reena | director | A-Award | 375 | — |
| Oct 1, 26 | Connor Frank T | director | A-Award | 375 | — |